Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy

Overview of attention for article published in Frontiers in Bioengineering and Biotechnology, April 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter: 4 X users

patent: 1 patent

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

METHOD FOR EVALUATING SEVERITY RISK OF CORONAVIRUS INFECTIOUS DISEASE, AND SEVERITY RISK…

Application WO-2023007809-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.